Foundation News

The Crohn’s & Colitis Foundation, the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD®, the nation’s largest medical education learning platform for healthcare professionals, have partnered to deliver exclusive content to ReachMD learners.

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) announced today that they are partnering to co-sponsor the first-ever “Crohn’s & Colitis Congress,” which will take place in Las Vegas in January 2018.

Researchers have successfully identified biological signatures in pediatric patients with newly diagnosed Crohn’s disease (CD) capable of predicting whether a child will develop disease-related complications requiring major surgery within three to five years. The results of this research, “Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study,” have been published today in the high impact factor journal, The Lancet.

For the past 50 years, the Crohn’s & Colitis Foundation of America has worked to improve the lives of patients living with Crohn’s disease and ulcerative colitis, and to find cures for these debilitating digestive diseases. Today, the Foundation unveiled its new brand, which includes a new brand message, “uniting to care and cure,” and a new logo with a unifying symbol reflecting the organization’s commitment to the IBD community. In addition, the Foundation has amended its name to the Crohn’s & Colitis Foundation to place greater emphasis on its mission to cure these debilitating digestive diseases.

Today, the Crohn's & Colitis Foundation announced the launch of IBD Qorus™, a ground-breaking collaboration between patients and their healthcare providers that will lead to enhanced health outcomes and improve the quality of care for inflammatory bowel disease (IBD) patients.

The Crohn's & Colitis Foundation announced that it is developing an IBD Clinical Trials Community with the goal of educating and supporting IBD patients interested in participating in clinical trials.